Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Kuros Biosciences AG       CH0325814116

KUROS BIOSCIENCES AG

SummaryChartsNewsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Kuros Biosciences : Signs Agreement to Supply SeaSpine with Bone Graft Incorporating Kuross Advanced Submicron Surface Technology

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2019 | 05:59am EDT

Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders. Under the agreement Kuros will supply the bone graft in various forms and SeaSpine will market the products under the brand name OsteoCurrent in the U.S. and other select markets in Europe, South America and the Middle East providing the necessary regulatory approvals are achieved. Initial sales in the U.S. are expected prior to the end of H1 2019. Terms of the agreement were not disclosed.

Kuross proprietary bone graft technology comprises biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique topography, it preferentially directs early wound healing toward the bone-forming pathway, resulting in predictable healing, reliable fusions and an osteoinductive claim in Europe.

Joost de Bruijn, Chief Executive Officer of Kuros, said This is an important agreement, which demonstrates the interest of global orthobiologic companies in Kuross technologies and should allow greater penetration of our bone grafting technologies into the US, and other markets. We look forward to working together with SeaSpine to make OsteoCurrent a success and to improving the bone grafting options for surgeons.

Keith Valentine, Chief Executive Officer of SeaSpine, said We are excited to partner with Kuros to provide OsteoCurrent to our SeaSpine distributor partners, their surgeons and patients. We believe OsteoCurrent represents a best of class pure synthetic that will strengthen our product offering.

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
SEASPINE HOLDINGS CORP -1.44% 12.99 Delayed Quote.-28.78%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KUROS BIOSCIENCES AG
07/09Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution o..
GL
06/26Kuros Biosciences to propose adjustment of authorized and conditional capital..
TE
05/21Annual General Meeting of Kuros Biosciences approves certain resolutions
TE
04/11KUROS BIOSCIENCES : Enters Convertible Bond Financing Agreement For Up To CHF 5 ..
AQ
02/13KUROS BIOSCIENCES : SeaSpine and Kuros Biosciences sign bone graft agreement
AQ
02/13KUROS BIOSCIENCES : Signs Agreement to Supply SeaSpine with Bone Graft Incorpora..
AQ
02/11SEASPINE : Kuros Biosciences Signs Agreement to Supply SeaSpine with Bone Graft ..
AQ
2018KUROS BIOSCIENCES : raises $16m for bone-growth protein
AQ
2018KUROS BIOSCIENCES : Ends Transformational Year With First MagnetOs Sales, Lead C..
AQ
2018KUROS BIOSCIENCES : Announces Results of Rights Offering Capital Increase Will b..
AQ
More news
Chart KUROS BIOSCIENCES AG
Duration : Period :
Kuros Biosciences AG Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Joost D. de Bruijn Chief Executive Officer
Christian Martin Itin Chairman
Michael Grau Chief Financial Officer
Pascal Longlade Chief Technology Officer
Gerhard Ries Director
Sector and Competitors
1st jan.Capitalization (M$)
KUROS BIOSCIENCES AG3.91%26
GILEAD SCIENCES8.82%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.16%31 857
SAREPTA THERAPEUTICS INC43.04%11 437
GENMAB9.70%11 148